Dayra Therapeutics, Inc

Based in the US, Dayra Therapeutics, Inc specializes in developing and commercializing innovative therapeutic solutions that target chronic diseases and rare conditions, utilizing advanced biopharmaceutical technologies. Founded in 2024, Dayra Therapeutics, Inc is focused on creating therapeutic solutions for unmet medical needs. The company successfully raised USD 70. 00 mn in Seed funding from investors Biogen and Versant Ventures on November 24, 2025.

The firm has engaged in one investment deal to date, showcasing its commitment to advancing healthcare solutions. Dayra Therapeutics specializes in the development and commercialization of innovative therapeutic solutions designed to meet unmet medical needs. The company's core offerings focus on advanced treatments aimed at addressing chronic diseases and rare conditions, utilizing biopharmaceutical technologies. These products are engineered to enhance patient outcomes by providing targeted therapies that improve efficacy and minimize side effects.

Dayra Therapeutics primarily serves healthcare providers, hospitals, and clinics across North America and Europe, facilitating access to its products for a diverse patient population. Dayra Therapeutics generates revenue through a multifaceted business model that includes direct sales to healthcare institutions and partnerships with distributors. The company employs a tiered pricing structure for its flagship therapeutic products, allowing for flexibility based on client needs and the scale of purchase. Transactions are primarily structured as business-to-business engagements, with hospitals and clinics placing bulk orders for treatment regimens.

Additionally, Dayra Therapeutics may engage in strategic partnerships with other biotech firms and healthcare organizations to broaden its market reach and enhance its product offerings, supported by a solid client base that ensures a sustainable financial foundation for continued growth and product development. With the recent Seed funding of USD 70. 00 mn raised on November 24, 2025, Dayra Therapeutics plans to accelerate the development of new products targeting chronic conditions and rare diseases. The company aims to expand its market presence in Europe and Asia by 2026, leveraging the funds to enhance its research capabilities and increase production capacity.

These strategic initiatives are designed to bolster Dayra Therapeutics' growth trajectory and improve healthcare outcomes across diverse patient populations.